☆ 4.7 Article

Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study

ANNALS OF ONCOLOGY (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Real-world data on microsatellite instability status in various unresectable or metastatic solid tumors

Kiwamu Akagi et al.

Summary: Microsatellite instability-high (MSI-H) is an important biomarker for predicting the effect of immune checkpoint inhibitors (ICIs) on advanced solid tumors. The frequency of MSI-H varies by cancer type, gender, and age, which should be taken into consideration when planning ICI therapy. This study investigated the results of MSI tests conducted in clinical practice, revealing a higher frequency of MSI-H in female patients and in younger or older age groups.

CANCER SCIENCE (2021)

添加到收藏夹

Article Immunology

Tumor-Infiltrating Lymphoid Cells in Colorectal Cancer Patients with Varying Disease Stages and Microsatellite Instability-High/Stable Tumors

Salman M. Toor et al.

Summary: The study found differential expression of immune checkpoints on lymphoid cells in colorectal cancer tumors compared to normal colon tissue, with specific gene low expression associated with poorer progression-free interval. Assessment of functionality has the potential to uncover resistance mechanisms to immune checkpoint inhibition.

VACCINES (2021)

添加到收藏夹

Article Pathology

DNA mismatch repair proteins: scientific update and practical guide

Adrian C. Bateman

Summary: MMR proteins are crucial for detecting and correcting genetic mutations during DNA replication. Deficient MMR function can increase the risk of neoplasia, indicate Lynch syndrome, and affect responses to chemotherapy and immunotherapy.

JOURNAL OF CLINICAL PATHOLOGY (2021)

添加到收藏夹

Article Critical Care Medicine

Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study

Timothy A. Yap et al.

Summary: Pembrolizumab demonstrated durable antitumor activity and manageable toxicity in patients with advanced MPM, regardless of PD-L1 status. Our data support the programmed death 1 (PD-1) and PD-L1 pathway as a potential therapeutic target in some patients with previously treated mesothelioma but biomarkers that can effectively identify such patients are yet to be elucidated.

LANCET RESPIRATORY MEDICINE (2021)

添加到收藏夹

Meeting Abstract Oncology

A phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced unresectable ormetastatic microsatellite instability-high/mismatch repair deficient solid tumors.

Jian Li et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study

Nilofer S. Azad et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Meeting Abstract Oncology

Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study

Aurelien Marabelle et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164

Dung T. Le et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors

Mohamed E. Salem et al.

INTERNATIONAL JOURNAL OF CANCER (2020)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer

T. Andre et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Medicine, Research & Experimental

Association of programmed death ligand 1 expression with prognosis among patients with ten uncommon advanced cancers

Torben Steiniche et al.

FUTURE SCIENCE OA (2020)

添加到收藏夹

Article Oncology

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study

Aurelien Marabelle et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Meeting Abstract Oncology

Safety and clinical activity of durvalumab monotherapy in patients with microsatellite instability high (MSI-H) tumors.

Neil Howard Segal et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Review Oncology

ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach

C. Luchini et al.

ANNALS OF ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study

Hyun Cheol Chung et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Review Oncology

Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data

Pauline du Rusquec et al.

CANCER MANAGEMENT AND RESEARCH (2019)

添加到收藏夹

Article Oncology

Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer

Panagiotis A. Konstantinopoulos et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Article Oncology

T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028

Patrick A. Ott et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

Michael J. Overman et al.

LANCET ONCOLOGY (2017)

添加到收藏夹

Article Multidisciplinary Sciences

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

Dung T. Le et al.

SCIENCE (2017)

添加到收藏夹

Review Oncology

Microsatellite Instability as a Biomarker for PD-1 Blockade

Jonathan C. Dudley et al.

CLINICAL CANCER RESEARCH (2016)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Roy S. Herbst et al.

LANCET (2016)

添加到收藏夹

Article Medicine, General & Internal

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

D. T. Le et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

添加到收藏夹

Article Oncology

The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints

Nicolas J. Llosa et al.

CANCER DISCOVERY (2015)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.